There is no slowdown in sight, says Avid Bioservices CEO, as the company today announces further expansion to support new client projects and optimize its novel CHO-based expression system.
Roger Lias, CEO of Avid Bioservices said the company has seen a “tremendous surge” in interest since formally transitioning to a full-service, dedicated CDMO
Lias said: “Our announced expansion is driven by strong in interest in our process development & clinical stage services, but we are also in the unusual position of having multiple single use 2,000L bioreactors
4-24-18/PR: Avid adding Process Dev. Labs, upgrading capabilities (in phases; total will be >6000sq; 1st one ready Q3/CY’18(July-Sept'18). ”In recent weeks, Avid has signed new agreements with 3 addl. undisclosed intl. drug dev. companies (that’s 4 thus far in CY2018)”
Looks like Roger has to confirm things are still up to speed
Market Data 
Markets 
AI
